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The Report from a committee convened by the Institute of Medicine updating the 
dietary reference intakes for calcium and vitamin D for the US and Canada makes a 
positive contribution to our understanding of the role of dietary calcium and vitamin D 
in bone health (1).  The systematic approach to the review of the evidence base is 
particularly welcome.  While the committee does not substantially change 
recommended dietary intakes for calcium and modestly increases those for vitamin 
D, the Report’s greatest significance lies in the qualitative conclusions it reaches and 
in its re-examination of target levels for serum 25-hydroxyvitamin D.  The key 
messages are that current evidence does not support non-skeletal benefits for 
vitamin D or calcium, that most North Americans have adequate levels of both, and 
that higher intakes could have adverse health consequences.  These conclusions are 
supported by 1,000 pages of evidence, mostly drawn from two previous systematic 
reviews (2,3), which form a valuable reference source for people working in this area, 
though they are not completely up to date or comprehensive.  For example, the 
systematic reviews did not search important, relevant databases such as Embase, 
and sought English language publications only.  Some key randomized trials and 
systematic reviews in the area were not included.  The Report undervalues recent 
systematic reviews other than those it commissioned.  It makes very little reference 
to recently published individual patient meta-analyses (4,5) which have clinical and 
statistical advantages over trial level meta-analyses (6).  
 
A recurrent theme throughout the Report is the limitations of the evidence base which 
underpins these recommendations.  Those for calcium intake are substantially based 
on balance studies.  In adults, in particular, it is bone balance, not calcium balance, 
that is critical, and the inability of the calcium balance technique to assess bone 
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balance has led to it being replaced by measurements of bone mineral density (BMD) 
in most studies in adults.  While it is possible to achieve positive calcium balances 
with high calcium intakes, sustained increases in bone mineral density from calcium 
supplementation have not been demonstrable (7).  The precision of the 
recommended average calcium requirements belies the imprecision of the balance 
techniques on which they are based.  In the Report, postmenopausal women are 
said to require 200 mg/day more calcium, yet there is no evidence that an increment 
of this magnitude has any effect on BMD, let alone fractures.  The fundamental 
effects of menopause on the skeleton are mediated by the fall in estrogen levels (8), 
and can only really be mitigated by replacement of estrogen or the use of 
pharmaceuticals of comparable antiresorptive potency, such as bisphosphonates.  
Calcium supplementation, even in large doses, is only a comparatively weak 
resorption inhibitor.  This is reflected by the small effect of calcium supplementation 
on total fractures (9).  Unfortunately, the Report overlooks the evidence that calcium 
supplement monotherapy actually appears to increase hip fracture risk (10,11), and 
to consider the impact of this on the balance of risk-benefit. 
 
The appropriateness of having dietary allowances for vitamin D is open to question.  
The Report states that vitamin D is an essential nutrient, which is an error created by 
the misnaming of this compound.  Most of the world’s population derives very little of 
their vitamin D requirement from the diet, so it is more accurately regarded as a pro-
hormone synthesized in the skin. Its serum levels reflect factors such as cutaneous 
ultraviolet light exposure, skin color, extent of skin exposed, age, obesity and 
exercise, as well as dietary influences.  Understanding these factors leads to an 
understanding of who is at risk of vitamin D deficiency, and of appropriate strategies 
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for preventing and treating deficiency.  The statement in the Report that ‘vitamin D 
requirements could not address the level of sunlight exposure because public health 
concerns about skin cancer preclude this possibility’ is surprising.  Sunlight exposure 
is a normal part of most people’s life and the implication that it should be universally 
avoided is without an evidence base.  Other groups have quantified the extent of 
sunlight exposure which is necessary to maintain normal vitamin D status and have 
provided a practical recommendation as to how this can be achieved while 
minimizing the risk of skin cancer (12).  Promulgation of such recommendations is 
more likely to produce optimal outcomes for both skin and bone health than an 
implied ban on venturing outdoors.  The inappropriateness of ignoring sunlight as a 
vitamin D source is reflected in the fact that a minority of North Americans achieve 
the vitamin D intakes recommend by the committee but the majority have satisfactory 
serum levels of 25-hydroxyvitamin D.   
 
The committee provides a valuable re-analysis of how vitamin D deficiency should be 
defined. They begin by stating that ‘25-hydroxyvitamin D cannot be considered a 
validated health outcome surrogate’, a useful reminder of our limited understanding.  
A serum 25-hydroxyvitamin D of 50 nmol/L is described as covering the needs of 
97.5% of the population, the lower end of the requirement range is set at 30 nmol/L, 
and 40 nmol/L represents the median population requirement, and was used as the 
basis for calculating the Estimated Average Requirement. The seasonal fluctuation in 
25-hydroxyvitamin D of 20-30 nmol/L and the imprecision in its measurement (~10%) 
(13) need to be considered when implementing these guidelines.  The higher level of 
75nmol/L is not supported by the committee.  There has been a progressive upward 
redefinition of cut-offs for 25-hydroxyvitamin D in recent years, which has been 
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substantially based on observational data.  This has produced an epidemic of 
apparent vitamin D deficiency, leading to widespread use of vitamin D supplements 
in populations in whom benefits have yet to be demonstrated by randomized 
controlled trials.  The present report provides a timely reminder of the dangers of 
developing public health practice in this way, and contrasts with a less critical use of 
the evidence base by other bodies addressing this question (14).  The message that 
more is not necessarily better is an important product of this Report.  The lack of 
evidence for the non-skeletal benefits from vitamin D supplementation is also an 
important message.  Again, the suggestion that these effects might exist is mostly 
based on association studies, but the critical dependence of 25-hydroxyvitamin D 
levels on factors such as sunlight exposure, exercise and obesity, means that all 
association studies are potentially confounded.  Such studies provide a useful basis 
for hypothesis generation, but not for public health policy. 
 
In considering the safe upper limits for calcium intake, the Committee has based its 
conclusions on the risk of development of renal calculi, not really confronting the fact 
that the effects of dietary calcium and supplemental calcium on this endpoint appear 
to be different (15).  Separate recommendations should be made for these two forms 
of calcium intake.  They also downplay the probable cardiovascular risk associated 
with calcium supplements, possibly because these data have only been published 
very recently.  They provide false reassurance by stating that the Bolland individual 
patient data meta-analysis of the effects of calcium supplementation without vitamin 
D (4) is contradicted by the trial level meta-analysis of Wang (16), whereas the 
Bolland analysis included all three trials in the Wang paper along with data from a 
further eight trials that Wang did not have access to.  The Wang analysis found a 
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relative risk of cardiovascular events of 1.14 (0.93 – 1.41) which is quite consistent 
with the Bolland results. The Wang results are not significant because that analysis 
was underpowered.  This issue is critically important, because if the cardiovascular 
adverse effects of calcium supplements are accepted, then the recommended 
calcium intakes will need to be achieved by diet alone, which is challenging.  This will 
bring a renewed focus back on the strength of the evidence for reference intakes in 
this report. 
 
In conclusion, the present Report is a welcome recall to evidence-based practice in 
nutrition. Wherever possible, dietary interventions need to be based on randomized 
trials just as other interventions are. Any bioactive entity can have unanticipated, off-
target effects, so safety needs to be assessed as it would be for a pharmaceutical, 
particularly if supplements are used rather than sunlight or diet. Food constituents, 
such as calcium, may not act in the same way when re-packaged as a concentrated 
supplement. Finally, we should re-think the appropriateness of having dietary 
reference intakes for a compound like vitamin D which is not primarily derived from 
the diet.  Perhaps the Food and Nutrition Board should share this responsibility for 
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